RMD

ResMed Inc. 10-Q Summary: Period Ended December 31, 2005

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing equipment for the diagnosis and treatment of sleep-disordered breathing and respiratory disorders. The report covers the three and six months ended December 31, 2005. All share and per-share data have been retroactively adjusted to reflect a two-for-one stock split effected in September 2005.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 41% ($42.5 million) for the quarter and 43% for the six-month period compared to the prior year. Growth was driven by increased unit sales of flow generators and masks, as well as $14.6 million in incremental revenue from recent acquisitions (PolarMed, Pulmomed, Saime, Hoefner, Resprecare).
• Margin Compression: Gross margin decreased from 66% to 63% for the quarter. This was primarily due to a shift in sales mix toward the lower-margin domestic market and higher manufacturing costs in Australia due to a stronger Australian dollar.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 46% quarter-over-year, largely due to stock-based compensation ($3.6 million) and increased personnel to support growth and acquisitions. Research and development (R&D) expenses increased 10%.
• Accounting Changes: The company adopted SFAS 123(R) on July 1, 2005, requiring the recognition of stock-based compensation expense, which reduced reported net income by $3.4 million for the quarter and $6.0 million for the six-month period.

Guidance, Outlook, and Risks

• Debt Redemption: On January 5, 2006, the company exercised its right to call for early redemption of $113.3 million in convertible subordinated notes. The redemption is scheduled for March 3, 2006, at 100.8% of principal plus accrued interest. Holders may convert notes to common stock prior to March 2, 2006.
• Capital Expenditures: Significant capital spending ($63.2 million for the six months) is ongoing for a new R&D/administration facility in Sydney and a new corporate headquarters in San Diego. The company expects to fund these via cash on hand and operations.
• Acquisition Integration: The company is integrating recent acquisitions (PolarMed, Pulmomed) and restructuring German operations (ResMed Germany and MAP). Risks include failure to realize anticipated synergies or integration difficulties.
• Foreign Exchange: The company faces exposure to currency fluctuations, particularly the Australian dollar and Euro, which impact manufacturing costs and reported revenues. Hedging programs are in place but may not fully offset risks.
• Regulatory and Reimbursement: Risks include potential changes in third-party reimbursement rates, FDA regulatory delays for new products, and compliance with anti-kickback laws.

Investor Verification Checklist

• Convertible Note Conversion: Verify the extent to which holders of the $113.3 million convertible notes elect to convert to equity versus cash redemption, as this impacts dilution and cash liquidity.
• Working Capital Trends: Monitor accounts receivable days outstanding (70 days in Q3 vs. 66 days prior) and inventory levels, which grew 66% year-over-year, to ensure they align with sales velocity.
• Acquisition Milestones: Track performance milestones for PolarMed and Pulmomed, which could trigger additional contingent payments totaling up to $3.9 million.
• Stock-Based Compensation Impact: Assess the ongoing impact of SFAS 123(R) on future earnings, with $12.9 million in unrecognized compensation costs remaining to be recognized over 1.8 years.
• German Tax Audit: Monitor the status of the ongoing German tax audit for the years 1996-1998, which could result in material tax adjustments.